Last Updated: November 16, 2026

Patent: 10,004,679

« Back to Dashboard


Summary for Patent: 10,004,679
Title:Compositions of Amorphophallus konjac and methods for their use in skin care
Abstract: Compositions derived from an extract of Amorphophallus konjac and methods for their use in the treatment of skin conditions. The compositions of the invention find use in maintaining the health of the skin and treating a variety of skin conditions, including wrinkles and fine lines, loss of skin tone, and hyperpigmentation. Without being limited to any particular theory or mechanism, the compositions of the invention treat skin conditions through the inhibition of enzymes, including but not limited to, collagenase, elastase and tyrosinase.
Inventor(s): Prasad; Kodimule Shyam (Bangalore, IN)
Assignee: Vidya Herbs, Inc. (Fullerton, CA)
Application Number:14/975,863
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

US Patent 10,004,679: Claim Scope, Patent Strength, Expiration Risk, and Competitive Landscape

US Patent 10,004,679 covers skin-treatment methods and a topical or oral composition based on an Amorphophallus konjac tuber extract that is substantially free of glucomannan. The central limitation is not konjac generally. It is a defined extraction process in which alcohol causes glucomannan to form a coagulate that is removed, producing the claimed extract. The patent also claims use for wrinkling, loss of skin tone or turgor, dryness, hyperpigmentation, and related cosmetic conditions, as well as a konjac-extract and ceramide composition in an approximately 1:1.7 ratio. [1]

The estate is technically narrow but commercially relevant to products using a de-glucomannan konjac extract, particularly products combining that extract with ceramide. The principal enforcement questions are whether a competing product uses the claimed extraction process or a materially equivalent process, whether the finished product contains the claimed extract, and whether the product is used or marketed for a claimed skin condition.

What does US Patent 10,004,679 cover?

The patent has three claim groups:

Claim group Claims Subject matter Principal limiting features
Treatment methods 1-15, 18-19 Treating a skin condition with konjac extract Alcohol extraction, glucomannan coagulate removal, substantially glucomannan-free extract
Composition 16-17, 20 Konjac extract and ceramide composition Approximately 1:1.7 extract-to-ceramide ratio; same extraction limitations
Process-dependent limitations 18-20 Filtration embodiment Coagulate removed by filtration; extract is a filtrate

Independent claim 1 requires all of the following:

  1. A subject with a skin condition.
  2. Administration of a composition containing an Amorphophallus konjac tuber extract.
  3. An extract substantially free of glucomannan.
  4. An alcohol-contact extraction process.
  5. Formation of a glucomannan coagulate.
  6. Removal of that coagulate.
  7. An extract capable of inhibiting tyrosinase, elastase, collagenase, or combinations of those enzymes.
  8. Treatment of the skin condition.

Independent claim 10 is similar but omits the enzyme-inhibition requirement. Independent claim 16 is a product claim covering konjac extract and ceramide at an approximately 1:1.7 ratio.

How strong are the independent claims?

Claim 10 is potentially the broadest treatment claim because it does not require proof of tyrosinase, elastase, or collagenase inhibition. It still requires the accused product to contain an extract made through the specified alcohol-contact and coagulate-removal process.

Claim 16 is potentially the most commercially important claim because it directly targets a composition rather than conduct by an end user. A product manufacturer, contract manufacturer, or brand owner could face direct infringement exposure if its composition satisfies the ratio and extraction limitations.

The claims have both structural and process limitations:

Limitation Scope effect
Amorphophallus konjac tuber Excludes extracts from unrelated botanical sources
Alcohol contact Requires an alcohol-based extraction step
Glucomannan coagulate Requires a particular separation mechanism or result
Removal of coagulate Narrows the claim to a de-glucomannan process
Substantially free of glucomannan Creates an analytical product limitation
About 100 micrograms/mL Applies only to dependent claims 7 and 13
Extract-to-ceramide ratio of about 1:1.7 Applies to claims 8, 14, and independent composition claim 16
Filtration and filtrate Applies to claims 18-20

The use of “about” gives some numerical flexibility for the 1:1.7 ratio and 100 microgram/mL concentration. The exact range would depend on the specification, prosecution history, claim construction, and evidence regarding how a skilled person would understand the term.

What formulations are protected by US Patent 10,004,679?

Claims 9 and 15 list a wide range of dosage and delivery forms, including powders, tablets, capsules, solutions, sprays, suspensions, emulsions, ointments, creams, lotions, gels, drops, patches, gummies, and injections.

That list does not eliminate the core extraction requirements. A cream, capsule, gummy, or injection is within the claim only if it also contains the required konjac extract and satisfies the applicable treatment or composition limitations.

The formulation claims therefore provide breadth at the dosage-form level but limited freedom at the active-ingredient level. A competitor cannot avoid the patent merely by changing a cream to a capsule if the same claimed extract is used.

The ceramide ratio is particularly important. Claim 16 covers a composition comprising konjac extract and ceramide at approximately 1:1.7. A product using the same extract but a materially different ceramide ratio may avoid claim 16, although it could remain exposed under treatment claims 1 or 10 if the product is administered to treat a covered skin condition.

What skin conditions are protected?

Claims 2, 3, 4, and 5 identify the principal indications:

  • Wrinkling
  • Loss of skin turgor
  • Loss of skin tone
  • Dryness
  • Hyperpigmentation

Claim 3 links hyperpigmentation treatment to tyrosinase inhibition. Claims 4 and 5 link anti-aging conditions to elastase or collagenase inhibition.

The claims are drafted as methods of treating a skin condition, not simply as methods of improving cosmetic appearance. That distinction can affect infringement analysis, labeling strategy, regulatory classification, and induced-infringement risk. Product marketing that expressly links the extract to hyperpigmentation, collagenase inhibition, elastase inhibition, or wrinkle reduction would be more relevant than neutral ingredient marketing.

What is the patent’s key technical distinction?

The patent distinguishes the claimed extract from conventional konjac products dominated by glucomannan. Glucomannan is a polysaccharide associated with the viscosity and fiber properties of konjac. The claimed process instead uses alcohol to produce a glucomannan coagulate and removes that material.

The resulting extract is defined by both process and composition:

  • Process: alcohol contact, coagulate formation, coagulate removal.
  • Product: extract substantially free of glucomannan.
  • Functional activity: potential inhibition of tyrosinase, elastase, or collagenase.

This creates a hybrid claim structure. A competitor may face infringement under a product claim based on the composition, while the patent owner may rely on the process language to establish that the extract originated from the claimed manufacturing route.

How can a competitor design around the patent?

The most credible design-around strategies target the extraction process, the botanical source, the active composition, or the use case.

Design-around approach Potential effect
Use a non-konjac botanical extract Avoids the Amorphophallus konjac limitation
Use konjac extract made without alcohol May avoid the express alcohol-contact limitation
Remove glucomannan by a different process May avoid literal process infringement, subject to equivalents
Retain substantial glucomannan May avoid the “substantially free” limitation, but creates product-performance differences
Use a different konjac plant part May avoid the tuber limitation
Use a materially different ceramide ratio May avoid claim 16
Avoid treatment claims in labeling May reduce method-of-use and induced-infringement exposure
Use a different active for pigmentation or anti-aging May reduce overlap with the functional limitations in claim 1

The strongest design-around is likely a product that uses a different plant part or a konjac extract produced without the claimed alcohol-induced coagulation step. That strategy requires process documentation and analytical testing. A supplier certificate stating “konjac extract” is not sufficient to establish non-infringement.

The doctrine of equivalents remains a risk where a competitor uses a different separation technique that performs substantially the same function in substantially the same way to produce substantially the same result. The scope of that risk depends on prosecution history and any amendments or arguments made during examination.

When does US Patent 10,004,679 lose exclusivity?

The patent issued on June 26, 2018. [1] Patent expiration is ordinarily governed by 35 U.S.C. §154 and is generally 20 years from the earliest effective U.S. nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and continuity rules. [2]

The patent number and issued claims alone do not establish a reliable expiration date. A final term calculation requires the patent’s earliest effective nonprovisional filing date, any priority claims, patent-term adjustment, and terminal-disclaimer information.

Because the patent claims a cosmetic or therapeutic method and composition rather than an approved small-molecule prescription drug, Hatch-Waxman exclusivity does not automatically apply. Patent expiration and FDA regulatory exclusivity are separate issues.

What is the Orange Book status of US Patent 10,004,679?

US Patent 10,004,679 is not, based on the claim subject matter supplied, an Orange Book patent in the ordinary pharmaceutical sense. The Orange Book identifies patents submitted by sponsors for approved drug products, including patents covering drug substances, drug products, and approved methods of use. [3]

A cosmetic cream, dietary supplement, or general wellness product would not ordinarily generate an Orange Book listing. An FDA-approved drug product containing the claimed konjac extract could raise a separate listing question, but patent eligibility for listing would depend on the approved product, the NDA, and the relationship between the claims and the approved labeling.

The patent therefore presents commercial IP risk without necessarily creating an Orange Book-based generic-delay mechanism.

Are Paragraph IV challenges relevant?

A Paragraph IV certification is relevant when an ANDA applicant seeks approval for a generic drug and challenges an Orange Book-listed patent as invalid, unenforceable, or not infringed. [4]

For a cosmetic or supplement product, Paragraph IV is generally not the applicable challenge pathway. A competing manufacturer would more likely face:

  • A patent infringement action under 35 U.S.C. §271.
  • A declaratory judgment action.
  • A licensing negotiation.
  • A product redesign.
  • A challenge based on invalidity, non-infringement, written description, enablement, or indefiniteness.

If a later NDA product incorporates the claimed extract and the patent is properly listed, Paragraph IV could become relevant. The supplied claim set does not establish that such an NDA product exists.

What patent litigation and settlement agreements affect the patent?

The supplied patent claims do not identify litigation, settlements, licenses, or assignments. No litigation conclusion should be drawn from the claim language alone.

For diligence purposes, the relevant questions are:

Diligence issue Commercial significance
Patent ownership and assignments Determines the party with enforcement authority
Reexamination or post-grant proceedings May alter claim validity or scope
Continuation applications May preserve related claims after the patent expires or narrows
Litigation history May provide claim-construction and validity positions
License agreements May affect freedom to operate and royalty burden
Prosecution-history estoppel May limit doctrine-of-equivalents arguments
Terminal disclaimer May alter the effective expiration date

A search should cover the USPTO Patent Center, Patent Examination Data System records, assignment database, federal court dockets, and International Trade Commission records. The patent’s commercial value cannot be assessed solely from the issued claims if continuation patents or contractual restrictions exist.

How does this patent compare with ordinary konjac and ceramide patent estates?

US Patent 10,004,679 is narrower than a generic patent covering konjac as a cosmetic ingredient. Its value comes from the combination of:

  1. A specific botanical source.
  2. A defined extraction and separation process.
  3. A low-glucomannan product characteristic.
  4. Skin-treatment applications.
  5. A ceramide combination at a specified ratio.

A conventional ceramide patent may cover barrier repair, moisturization, or lipid mixtures without requiring konjac. A conventional konjac patent may cover glucomannan, dietary fiber, viscosity, or gel formation. Those estates may not overlap directly with this patent.

The highest overlap risk exists for a product that uses a low-glucomannan konjac extract as an anti-aging or depigmenting active and combines it with ceramide.

What is the generic and competitive entry risk?

The patent does not create conventional generic-drug entry risk because the claimed products are likely to be marketed as cosmetics, supplements, or specialty ingredients rather than ANDA products. The principal risk is competitive launch risk.

A rival can enter with:

  • A different botanical extract.
  • A konjac extract with a different manufacturing route.
  • A formulation that does not contain ceramide.
  • A different ceramide ratio.
  • Claims limited to moisturization rather than treatment of the specified conditions.
  • A product that retains glucomannan rather than removing it.

The patent is stronger against vertically integrated competitors that purchase or manufacture the same specialized extract and market it for the claimed indications. It is weaker against companies using functionally similar but chemically or botanically different actives.

Key Takeaways

  • US Patent 10,004,679 is centered on a substantially glucomannan-free Amorphophallus konjac tuber extract.
  • The defining process is alcohol treatment followed by formation and removal of a glucomannan coagulate.
  • Claim 10 is the broadest treatment claim because it does not require enzyme-inhibition evidence.
  • Claim 16 is commercially important because it directly covers a konjac-extract and ceramide composition at approximately a 1:1.7 ratio.
  • The formulation list is broad, but every covered product must still satisfy the central extract limitations.
  • Orange Book and Paragraph IV mechanisms are generally not implicated by the supplied claim set unless an approved NDA product and a qualifying listing exist.
  • The most practical design-arounds involve changing the botanical source, extraction process, glucomannan content, ceramide ratio, or product labeling.
  • A reliable expiration date requires the patent’s full priority, continuity, patent-term-adjustment, and terminal-disclaimer records.
  • The patent’s enforceability and commercial value depend heavily on supplier process records, analytical testing, prosecution history, and any continuation or licensing activity.

FAQs About US Patent 10,004,679

Does the patent cover all konjac extracts used in skin-care products?

No. It requires an Amorphophallus konjac tuber extract that is substantially free of glucomannan and made through the specified alcohol-contact and coagulate-removal process.

Can a company avoid the patent by using a konjac extract containing glucomannan?

Possibly, but the result depends on the amount of glucomannan and whether the extract was made through the claimed process. Product testing and manufacturing records would be important.

Does the 1:1.7 ceramide ratio apply to every claim?

No. It is expressly required by claims 8, 14, and 16. The broader treatment claims do not universally require ceramide.

Is a topical cream automatically covered by the patent?

No. A cream is only one listed dosage form. The product must also contain the required extract and satisfy the relevant treatment, process, or composition limitations.

Can a supplier’s konjac extract create infringement risk for a brand owner?

Yes. A brand owner can face risk if its finished product contains the claimed extract and is marketed or used for a covered skin condition, even if the brand owner did not perform the extraction process itself.

References

  1. United States Patent No. 10,004,679, claims 1-20 (issued June 26, 2018).

  2. 35 U.S.C. §154. Patent term.

  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book).

  4. 21 U.S.C. §355(j)(2)(A)(vii)(IV). Abbreviated new drug applications and Paragraph IV certifications.

More… ↓

⤷  Start Trial

Details for Patent 10,004,679

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Smith & Nephew, Inc. SANTYL collagenase Ointment 101995 June 4, 1965 ⤷  Start Trial 2035-12-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.